# A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

> **NCT07406282** · — · RECRUITING · sponsor: **Bayer** · enrollment: 1400 (estimated)

## Conditions studied

- Prostatic Neoplasms
- Metastatic Hormone-Sensitive Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Abiraterone acetate
- **DRUG:** Enzalutamide
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT07406282
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07406282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07406282, "A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07406282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*